يعرض 1 - 2 نتائج من 2 نتيجة بحث عن '"ISM, Indolent systemic mastocytosis"', وقت الاستعلام: 0.35s تنقيح النتائج
  1. 1

    المصدر: Journal of Allergy and Clinical Immunology, 146(2), 300-306. MOSBY-ELSEVIER
    The Journal of Allergy and Clinical Immunology
    Valent, P, Akin, C, Bonadonna, P, Brockow, K, Niedoszytko, M, Nedoszytko, B, Butterfield, J H, Alvarez-Twose, I, Sotlar, K, Schwaab, J, Jawhar, M, Reiter, A, Castells, M, Sperr, W R, Kluin-Nelemans, H C, Hermine, O, Gotlib, J, Zanotti, R, Broesby-Olsen, S, Horny, H P, Triggiani, M, Siebenhaar, F, Orfao, A, Metcalfe, D D, Arock, M & Hartmann, K 2020, ' Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic : Expert opinions ', Journal of Allergy and Clinical Immunology, vol. 146, no. 2, pp. 300-306 . https://doi.org/10.1016/j.jaci.2020.06.009
    Journal of Allergy and Clinical Immunology

    مصطلحات موضوعية: 0301 basic medicine, MIDOSTAURIN, coronavirus, COVID-19, KIT D816V, mast cell activation syndrome, Mast cells, mastocytosis, SARS-CoV-2, tryptase, Betacoronavirus, Comorbidity, Coronavirus Infections, Diphosphonates, Expert Testimony, Glucocorticoids, Histamine Antagonists, Humans, Immunosuppressive Agents, Mast Cells, Mastocytosis, Cutaneous, Mastocytosis, Systemic, Myeloablative Agonists, Pneumonia, Viral, Precision Medicine, Risk Factors, Vitamin D, Disease Management, Pandemics, medicine.medical_treatment, Hematopoietic stem cell transplantation, Disease, medicine.disease_cause, MCA, Mast cell activation, 0302 clinical medicine, Pandemic, INFECTION, Immunology and Allergy, CRITERIA, Viral, 030212 general & internal medicine, Systemic mastocytosis, MCAS, Mast cell activation syndrome, Coronavirus, BM, Bone marrow, CM, Cutaneous mastocytosis, SAFETY, MAST-CELLS, medicine.symptom, CELL ACTIVATION SYNDROMES, medicine.medical_specialty, DISORDERS, Immunology, Mast cell activation syndrome, DIAGNOSIS, Article, WHO, World Health Organization, CLASSIFICATION, KITD816V, 03 medical and health sciences, medicine, Intensive care medicine, SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2, Corona Virus, business.industry, Cutaneous Mastocytosis, Systemic, Pneumonia, medicine.disease, EFFICACY, Cutaneous, 030104 developmental biology, IgE, Immunoglobulin E, MC, Mast cells, SM, Systemic mastocytosis, COVID-19, Corona virus disease 2019, business, ISM, Indolent systemic mastocytosis

    وصف الملف: application/pdf

  2. 2

    المساهمون: Centre de référence des mastocytoses (CEREMAST), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Institut Necker Enfants-Malades (INEM - UM 111 (UMR 8253 / U1151)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Référence des Mastocytoses de Toulouse (CEREMAST), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne (UCA), Virus et Immunité - Virus and immunity (CNRS-UMR3569), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), The authors would like to thank Fondation Université de Paris, AXA research fund, Fondation Hôpitaux de Paris-Hôpitaux de France, Mécénat du GH APHP. CUP, Fondation pour la Recherche en Physiologie and DMU BioPhyGen for the funding of the COVID-HOP study., ANR-20-COV1-0001,APCOD,Les cellules présentatrices d'antigènes dans la maladie de COVID-19 à résolution monocellulaire(2020), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPC), CHU Toulouse [Toulouse], Virus et Immunité - Virus and immunity, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS)

    المصدر: The Journal of Allergy and Clinical Immunology. in Practice
    The Journal of Allergy and Clinical Immunology: In Practice
    The Journal of Allergy and Clinical Immunology: In Practice, 2022, 10 (5), pp.1356-1364.e2. ⟨10.1016/j.jaip.2021.12.038⟩
    The Journal of Allergy and Clinical Immunology: In Practice, American Academy of Allergy, Asthma & Immunology, 2022, 10 (5), pp.1356-1364.e2. ⟨10.1016/j.jaip.2021.12.038⟩